Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1164
IPSCIO Record ID: 281651
Licensor is an immuno-oncology company focused on innovative treatments based on the Companys proprietary NK cell engager (TriKEâ„¢) platform and Multi-Target Directed Bispecific Drug Conjugate platform.
Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The disease occurs in all ethnic groups and both genders. Myasthenia gravis most commonly affects adult women (onset between 20 to 40 years) and older men (onset over 60), but it can occur at any age (Myasthenia Gravis Fact Sheet; National Institute of Neurological Disorders and Stroke, 2016).
IPSCIO Record ID: 26578
IPSCIO Record ID: 295927
Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy?) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal). The muscle weakness usually worsens with age.
IPSCIO Record ID: 27459
FirdapseÂ® (currently approved in the EU) is the first and only approved drug for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome in adults, a rare autoimmune disease with the primary symptoms of muscle weakness.
Firdapse has been designated an orphan drug.